Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

779.28 +3.38 (+0.44%)
Official Closing Price Updated: 7:00 PM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Where will S&P 500 go after new bullish levels?
Major indexes look resilient despite 2024's rocky start, getting support at key moving averages. Upcoming earnings could be catalysts in either direction. 
Via MarketBeat
Topics ETFs Stocks
Can Simply Good Foods ride the GLP-1 weight loss trend in 2024?
Simply Good Foods may be ready to breakout as the GLP-1 medication weight-loss trend is driving up sales for its Atkins and Quest Nutrition branded products 
Via MarketBeat
Merck, the Dow's hottest stock, gets set to report Q4 financials
Up 5.7% year-to-date, pharmaceuticals - including MRK - are the best performing industry in the entire U.S. equity market, outpacing even biotech stocks. 
Via MarketBeat
Topics Stocks
HCA Healthcare Rallies: Weight-loss drugs really a big threat?
HCA Healthcare rebounds amid concerns about weight-loss drugs' impact. The healthcare giant's revenue growth hints at resilience despite sector challenges. 
Via MarketBeat
Topics ETFs
Eli Lilly and Company (NYSE: LLY) is a Leading Gainer in Thursday Morning Trading
Via Investor Brand Network
Eli Lilly and Company (NYSE: LLY) is a Stock Spotlight on 10/25
Via Investor Brand Network
Weight Watchers gains from Oprah’s GLP-1 weight-loss
Oprah Winfrey revealed she has lost over 60 pounds and is on the path to reaching her weight goal of 167 lbs. She credits this to taking GLP-1 medication 
Via MarketBeat
Topics Artificial Intelligence
LifeMD expands telehealth GLP-1weight-loss service with Medifast
LifeMD Inc. (NASDAQ: LFMD) is a direct-to-consumer (DTC) comprehensive virtual healthcare platform. The company offers per-visit and membership plan pricing 
Via MarketBeat
Can Altimmune's weight-loss drug be a game-changer?
The runaway success of weight-loss drugs like Novo Nordisk A/S (NYSE: NVO) Ozempic and Eli Lilly and Co. (NYSE: LLY) Mounjaro has kicked off a gold 
Via MarketBeat
Neuropsychiatric Disorders and Treatment Market Projected to Show Strong Growth: Astrazeneca, AviadoBio, Astellas Pharma
Get an extensive Neuropsychiatric Disorders And Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry. 
Via SBWire
Topics Artificial Intelligence
Ozempic vs. Mounjaro:: Battle of the bulge
The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs, led by the popularity of Ozempic. Celebrity usage 
Via MarketBeat
Doing Your Holiday Shopping? These Stocks Might Make Great Gifts
No matter which holiday you're planning gifts for, Christmas, Hanukkah, or some other occasion, there may be one great gift idea you haven't thought of yet. 
Via MarketBeat
Topics Bonds
Anti-Inflammatory Drugs Market Boosting the Growth Worldwide 2030
Get Anti-inflammatory Drugs Market analysis, key vendors & competitive scenario of the market prepared using market research tools such as Porter’s five forces and SWOT analysis. 
Via SBWire
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
These are the top sectors for blue chip growth in 2024
The sector results will be mixed in 2024 but the Health Care, Communications and Technology sectors (and some of their stocks) will post robust gains. 
Via MarketBeat
Topics Economy Intellectual Property
Increase Prevalence of Diabetic Patients Driving Market Growth Projected to Reach $55 Billion by 2029
EQNX::TICKER_START (OTCPK:CNER),(NASDAQ:PODD),(NASDAQ:TNDM),(NYSE:LLY),(NYSE:ABT) EQNX::TICKER_END 
Via FinancialNewsMedia
Type 1 Diabetes Market Comprehensive Study Explores Huge Growth by Key Players DiaVacs, XOMA Corp., Biodel, Macrogenics
Type 1 Diabetes Market Growth 
Via SBWire
MarketBeat Week in Review – 11/6 - 11/10
Stocks closed the week with a strong rally, but the rally may reverse when investors get the latest information about inflation and retail stocks next week 
Via MarketBeat
Topics Artificial Intelligence Economy
Will Eli Lilly's Zepbound be the next big weight-loss drug?
Eli Lilly got regulators' OK for weight-loss drug Zepbound, which will compete with Novo Nordisk's Wegovy. Analysts see Zepbound sales as high as $37 billion 
Via MarketBeat
Investor patience tested as pharmaceutical stocks take a tumble
The healthcare sector faces a selloff as pharmaceutical giants report lackluster earnings; even Amgen's strong results failed to prevent selling in the sector 
Via MarketBeat
J&J stock down as business unit mulls talc-related bankruptcy
Johnson & Johnson stock fell in the past week as talc-related lawsuits weigh on a subsidiary, which is mulling bankruptcy to mitigate payouts and settlements. 
Via MarketBeat
Topics Bankruptcy Lawsuit
Zenith Epigenetics Ltd. Announces Collaboration with Cencora on ZEN-3694
Calgary, Alberta--(Newsfile Corp. - October 25, 2023) - Zenith Epigenetics Ltd. ("Zenith" or the "Company"), a global leader in epigenetics,... 
Via Newsfile
Fighting the Silent Killer: Innovative Therapies for Pancreatic Cancer on the Rise
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(OTCQX:RHHBY),(NASDAQ:BNTX),(NASDAQ:ME) EQNX::TICKER_END 
Via FinancialNewsMedia
Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NYSE:LLY),(NYSE:ABBV),(NASDAQ:LIPO) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Is the Ozempic-Driven DexCom Selloff Overdone?
Has glucose monitor maker DexCom corrected too much on fears of lost sales due to weight loss and diabetes drugs made by Novo Nordisk and Eli Lilly? 
Via MarketBeat
Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race
Major pharmaceutical companies are continuing to make substantial acquisitions in the field of oncology, sparking enthusiasm in the market. Bristol Myers Squibb (NYSE:BMY) just announced its plan to... 
Via PressReach
Bristol Myers Squibb Joins Big Pharma’s Race to Dominate Oncology
Leading pharmaceutical companies are diving headfirst into oncology, sparking a buzz in the cancer treatment world. Bristol Myers Squibb is the latest company to join the movement, announcing its plan... 
Via PressReach
Eli Lilly and Company (NYSE: LLY) Sets New 52-Week High in Friday Session
Via Investor Brand Network
New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:PYXS),(NASDAQ:AZN),(NYSE:LLY),(NASDAQ:MRUS) EQNX::TICKER_END 
Via FinancialNewsMedia
Will Higher Ozempic Use Mean Slimmed-Down Food Sales?
Novo Nordisk's Ozempic, a weight loss drug, is making waves in the food industry, raising concerns about its effect on sales of calorie-laden products. 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.